News - Genzyme, Markets & Marketing


Popular Filters

Growing US uptake of Genzyme's Aubagio at three months post-launch


Some 34% of surveyed US neurologists have prescribed French drug major Sanofi (Euronext: SAN) subsidiary…

AubagioBiotechnologyGenzymeMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalSanofi

Genzyme says Lemtrada sBLA for MS accepted by FDA; reports on Aubagio


French drug major Sanofi (Euronext: SAN) US biotech subsidiary Genzyme says that the US Food and Drug…

AubagioBiotechnologyGenzymeLemtradaMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalRegulationSanofi

Sanofi moves on Lemtrada; Novartis Indian patent case


French drug major Sanofi's (Euronext: SAN) USA-based rare diseases subsidiary Genzyme is pulling leukemia…

Asia-PacificCampathEuropeGenzymeGlivecLegalLemtradaMarkets & MarketingNorth AmericaNovartisPatentsPharmaceuticalSanofi

Elelyso: a new therapeutic option for patients with Gaucher disease


The US Food and Drug Administration recently approved Protalix BioTherapeutic's (NYSE-AMEX: OLX) Elelyso…

CerezymeElelysoGenzymeMarkets & MarketingPfizerPharmaceuticalProtalix BioTherapeuticsRare diseasesShireVpriv

Genzyme to start shipping Fabrazyme from newly-approved plant


French drug major Sanofi's (Euronext: SAN) US subsidiary Genzyme says that it has begun shipping its…

BiotechnologyFabrazymeGenzymeMarkets & MarketingPharmaceuticalRare diseasesSanofi

Ongoing supply problems for Genzyme’s Cerezyme


US biotech Genzyme, now a subsidiary of French drug major Sanofi (Euronext: SAN), says it will have only…

BiotechnologyCerezymeFabrazymeGenzymeMarkets & MarketingPharmaceuticalRare diseasesSanofiShire

Back to top